Ovarian Cancer Diagnostics Market Expected To Encourage Expansion At A CAGR Of 6.2% For The Forecast Period From 2019 To 2026 : Grand View Research Inc.
San Francisco, 23 September 2019: The Report Ovarian Cancer Diagnostics Market Size, Share, & Trends Analysis Report By Diagnosis Type (Imaging, Blood Test), By Cancer Type (Epithelial Tumor, Stromal Cell Tumor), By End Use, By Region, And Segment Forecasts, 2019 – 2026
The global ovarian cancer diagnostics market size is expected to reach USD 2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.2%. The growth of the market can be attributed to an increase in the prevalence of ovarian cancer and emergence of novel diagnostic products. As of 2018, ovarian cancer had the highest mortality rate of all gynecologic cancers. It accounted for nearly 14,000 deaths in the U.S. in 2018. No specific symptoms render early diagnosis of the disease increasingly difficult. The exact causative factors remain unknown, creating a key unmet need for further research to obtain clarity on the underlying molecular mechanisms.
Women aged 60 years & above have a higher predisposition to it. As it is often diagnosed in advanced stages, treatment options are limited. Moreover, on the basis of race, incidence rates were higher among Caucasian women than African-American women. The International Federation of Gynecology and Obstetrics (FIGO) system is used for staging ovarian cancer. Staging process helps identify ovarian tumors, calculate their size, and detect invasion & metastasis.
Early detection and diagnosis significantly improve patient survival rates. For instance, in case of epithelial tumors, patients with stage 1 ovarian cancer have a survival rate of nearly 90%, whereas patients with stage 4-the most advanced phase-have a mere 15% survival rate. Technological advancements in PET and MRI as well as in diagnosis of BRCA mutations have positively impacted market growth.
The diagnostic landscape is gradually shifting toward genetic testing and counseling. As the disease bears a high risk of inheritance of gene mutation, guidelines pertaining to ovarian cancer diagnostics recommend all patients to undergo genetic counseling and testing. Earlier, BRCA1/2 was the most prominent test; however, advancements in medical science have now made it possible to test more than 20 genes in each patient.
Access Research Report of Ovarian Cancer Diagnostics Market @ www.grandviewresearch.com/industry-analysis/ovarian-cancer-diagnostics-market
Further key findings from the report suggest:
Grand View Research has segmented the global ovarian cancer diagnostics market on the basis of cancer type, diagnosis type, end use, and region:
Ovarian Cancer Diagnostics Cancer Type Outlook (Revenue, USD Million, 2015 - 2026)
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
The global ovarian cancer diagnostics market size is expected to reach USD 2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.2%. The growth of the market can be attributed to an increase in the prevalence of ovarian cancer and emergence of novel diagnostic products. As of 2018, ovarian cancer had the highest mortality rate of all gynecologic cancers. It accounted for nearly 14,000 deaths in the U.S. in 2018. No specific symptoms render early diagnosis of the disease increasingly difficult. The exact causative factors remain unknown, creating a key unmet need for further research to obtain clarity on the underlying molecular mechanisms.
Women aged 60 years & above have a higher predisposition to it. As it is often diagnosed in advanced stages, treatment options are limited. Moreover, on the basis of race, incidence rates were higher among Caucasian women than African-American women. The International Federation of Gynecology and Obstetrics (FIGO) system is used for staging ovarian cancer. Staging process helps identify ovarian tumors, calculate their size, and detect invasion & metastasis.
Early detection and diagnosis significantly improve patient survival rates. For instance, in case of epithelial tumors, patients with stage 1 ovarian cancer have a survival rate of nearly 90%, whereas patients with stage 4-the most advanced phase-have a mere 15% survival rate. Technological advancements in PET and MRI as well as in diagnosis of BRCA mutations have positively impacted market growth.
The diagnostic landscape is gradually shifting toward genetic testing and counseling. As the disease bears a high risk of inheritance of gene mutation, guidelines pertaining to ovarian cancer diagnostics recommend all patients to undergo genetic counseling and testing. Earlier, BRCA1/2 was the most prominent test; however, advancements in medical science have now made it possible to test more than 20 genes in each patient.
Access Research Report of Ovarian Cancer Diagnostics Market @ www.grandviewresearch.com/industry-analysis/ovarian-cancer-diagnostics-market
Further key findings from the report suggest:
- Incidence of ovarian cancer worldwide has been declining over the past decades
- Although ultrasound imaging is the fist-line of diagnosis, the technique cannot be used for staging the disease
- Computerized Tomography (CT) imaging is preferred for staging the disease
- CA125 remained the mainstay in blood test biomarkers in 2018
- HER2 and BRCA1/2 tests are expected to witness a rapid growth during the forecast period owing to the rising awareness of early diagnosis and genetic tests
- The ovarian cancer diagnostics market in Asia Pacific is expected to grow at a high rate during the forecast period.
Grand View Research has segmented the global ovarian cancer diagnostics market on the basis of cancer type, diagnosis type, end use, and region:
Ovarian Cancer Diagnostics Cancer Type Outlook (Revenue, USD Million, 2015 - 2026)
- Epithelial Tumor
- Germ Cell Tumor
- Stromal Cell Tumor
- Others
- Imaging
- Ultrasound
- CT Scan
- MRI Scan
- PET Scan
- Others
- Blood Test
- CA125
- HER2
- BRCA
- CEA
- ER & PR
- KRAS Mutation
- Others
- Biopsy
- Others
- Hospital Laboratories
- Cancer Diagnostic Centers
- Research Institutes
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
Comments
Post a Comment